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AbsTrACT
As intracerebral hemorrahge becomes more frequent as 
a result of an aging population with greater comorbidities, 
rapid identification and reversal of precipitators becomes 
increasingly paramount. The aformentioned population will 
ever more likely be on some form of anticoagulant therapy. 
Understanding the mechanisms of these agents and means 
by which to reverse them early on is critical in managing 
the acute intracerebral hemorrhage.
InTroduCTIon
Intracerebral haemorrhage (ICH) is a disease 
entity associated with high morbidity and 
mortality. It accounts for nearly 15% of all 
strokes.1 In the USA, the mortality rate of 
patients with ICH is nearly 34% confirming 
the increasing burden of the disease.2–4 Oral 
anticoagulation is a common cause of ICH 
and the use of oral anticoagulation is esti-
mated to continually rise given increasing rate 
of atrial fibrillation detection.5 Coagulopathy- 
associated ICH results in poor functional 
outcomes given rapid haematoma expansion 
as early as 1 hour.1–3
This article will review the indications, 
efficacy and safety of vitamin K antagonists 
(VKAs) as well as direct- acting oral anticoag-
ulants (DOACs) and outline the reversal of 
coagulopathy by these agents in ICH.
CompArIson of effICACy And sAfeTy 
beTween doACs And VKAs
Direct thrombin inhibitors and factor Xa 
inhibitors (FXa- Is) constitute the two classes 
of DOACs (table 1). Dabigatran (Pradaxa, 
Boehringer Ingelheim Pharmaceuticals) is 
a direct thrombin inhibitor, whereas rivar-
oxaban (Xarelto, Janssen Pharmaceuticals), 
apixaban (Eliquis, Bristol- Myers Squibb 
Company), edoxaban (Savaysa and Lixiana, 
Daiichi Sankyo) and betrixaban (Bevyxxa, 
Portola Pharmaceuticals) fall in the category 
of FXa- Is. DOACs do not require frequent 
monitoring of the international normalised 
ratio (INR) and have shorter half- lives with 
fewer drug interactions, making them more 
favourable for use than warfarin.6 Recent 
trials including ARISTOTLE (apixaban),7 8 
RE- LY (dabigatran),9 ROCKET AF (rivarox-
aban),10 ENGAGE AF- TIMI 48 (edoxaban)10 
on stroke and systemic embolism have shown 
non- inferiority of DOACs when compared 
with warfarin. The rate of bleeding (including 
major haemorrhage, fatal haemorrhage, 
haemorrhagic stroke or ICH) is also lower 
for DOACs at 3% to 4% when compared with 
warfarin at 5% to 6%. Additionally, the rate 
of only ICH is lower for DOACs at 0.3% to 
0.4% when compared with warfarin at 0.7% to 
0.8%.7–11
The rate of ischaemic stroke in patients 
taking DOACs has been noted to be higher 
when compared with warfarin.12–14 This could 
be explained by inconsistent use of DOACs 
resulting in subtherapeutic levels given their 
short half- lives.15
The outcome of ICH while on DOACs 
remains a topic for research. CROMIS-2 (The 
Clinical Relevance of Microbleeds in Stroke 
Study) compared all- cause 90- day mortality, 
functional outcome, ICH volume and haema-
toma expansion between patients with ICH 
associated with VKA and ICH associated with 
DOAC. There were no significant differences 
between the two groups.16 Other studies have 
shown similar functional outcomes in patients 
with ICH receiving VKA and DOACs and also 
mortality benefit in patients on DOACs.17 18
DOACs are becoming the preferred agents 
for oral anticoagulation when compared 
with VKAs given their safety profile.19 There 
is limited data on the reversal protocol of 
DOACs. As their use will continue to rise, it is 
imperative to understand the management of 
DOAC related ICH.
reVersAl of VKA-relATed CoAgulopAThy
pharmacology of VKAs
Warfarin interferes with production of 
vitamin K dependent clotting factors II, 
VII, IX, X by depleting vitamin K reserve.20 
Warfarin is metabolised by cytochrome P450 
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Table 1 Direct- acting oral anticoagulants (DOACs) and reversal
DOAC Brand name Mechanism of action Time to onset t1/2 Reversal
Dabigatran Pradaxa Direct thrombin inhibitor 0.5–2 hour 15 hours Idarucizumab
Rivaroxaban Xarelto Factor Xa inhibitor 2–4 hour 6–12 hour 3F- and 4F- PCC, andexanet alfa
Apixaban Eliquis 1–2 hour
Edoxaban Savaysa, Lixiana 1–2 hour Andexanet alfa
Betrixaban Bevyxxa 3–4 hour 24 hours
Table 2 Anticoagulant reversal agents and their pharmacokinetics
Anticoagulant reversal Brand name
Time to reverse 
coagulopathy t1/2
Terminal elimination 
t1/2
Idarucizumab Praxbind Minutes 47 m 10 hours
Prothrombin complex concentrate Kcentra 40 min factor dependent factor dependent
Fresh frozen plasma … >24 hour
Andexanet alfa Andexxa Minutes 1 hour 5–7 hour
enzyme, which can be inhibited or induced by a variety of 
drugs resulting in variable metabolism of warfarin.
reversal
Vitamin K is available in oral, subcutaneous and intra-
venous preparations for patients with life threatening 
bleeding. Intravenous vitamin K is most efficacious among 
the three with a recommended dose of 10 mg intrave-
nously.21 However, INR normalisation with vitamin K can 
take up to a day1–3 22 and therefore it is not sufficient alone 
in the management of ICH. It is usually given in combi-
nation with fresh frozen plasma (FFP) or prothrombin 
complex concentrate (PCC) (table 2).
FFP is the liquid portion derived from whole blood. It 
corrects coagulopathy by replacing plasma proteins to 
replete clotting factors. FFP reversal of INR can take up 
to 30 hours making it an ineffective treatment of early 
haematoma expansion.23–25 It requires high volumes and 
can worsen fluid balance in patients with heart failure 
resulting in pulmonary oedema as well as transfusion 
reactions.26
PCC is comprised of clotting factors II, IX and X at levels 
significantly higher than FFP. Activated PCC (aPCC) also 
contains factor VII in addition to II, IX and X. PCC results 
in rapid INR reversal and is not associated with complica-
tions such as fluid overload as seen with FPP.27 The INCH 
trial (International Normalised Ratio Normalisation 
in Coumadin- Associated Intracerebral Haemorrhage) 
compared 30 IU/kg dose of PCC to 20 mL/kg FFP in 
reversal of VKA associated ICH.25 PCC had a higher rate 
of INR reversal to <1.3 within 3 hours when compared 
with FFP (67% vs 9%; p=0.0003). The average time of INR 
reversal was 40 min in PCC group when compared with 
>24 hours for FFP and haematoma expansion was less for 
PCC group at 3 and 24 hours.28 The rate of thrombotic 
complications remains similar between PCC and FFP.29–32 
PCC (more than US$5000 for 20 IU/kg dose in a 70 kg 
patient) is more expensive when compared with FFP (less 
than US$2000 per unit), however it is more cost- effective 
given its advantages over FFP as outlined above. aPCC 
(20 IU/kg) is also found to be more efficacious than 
FFP without significant increase in thrombotic complica-
tions.33 There are no studies comparing aPCC to PCC to 
date.
reVersAl of doAC-relATed CoAgulopAThy
pharmacology of doACs
Dabigatran directly competes with thrombin, thus inhib-
iting production of fibrin. It has a half- life of approxi-
mately 15 hours and is primarily cleared by the kidneys.34 
FXa- Is act by binding and inhibiting factor Xa with 
half- lives of 6 to 12 hours, except for betrixaban which 
is approximately 24 hours.35 They are also primarily 
cleared by the kidneys.36 Unfortunately, unlike warfarin, 
dabigatran has no modality, which accurately measures its 
anticoagulation effect. Currently, specific anti- Xa assays 
are available for the FXa- Is but they are not widely avail-
able, have a complex measurement system and are rela-
tively expensive (over US$20 per test).37
reversal
In vitro studies have demonstrated PCC efficacy in reversal 
of DOAC anticoagulation.38–41 Ex vivo studies have been 
done on small populations of healthy male volunteers 
that proved the efficacy of both three factor PCC and four 
factor PCC at 50 IU/kg. Both types of PCC decreased PT 
within 30 min.42–44 Multiple trials have been conducted 
in actively bleeding patients (table 3). The UPRATE trial 
(Unactivated Prothrombin Complex Concentrates for 
the Reversal of Anti- Factor Ten Inhibitors) showed that 
four factor PCC reliably reversed 84 patients with major 
bleeding on apixaban and rivaroxaban (70% with ICH, 
15% with gastrointestinal bleed). The overall mortality 
was 32% at 30- day follow- up for both drugs.45–47
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Table 3 Summary of trials for anticoagulant reversal and haemorrhage treatment
Trial Anticoagulant
Anticoagulant 
reversal Primary endpoint Results
INCH25 VKA PCC, FFP Percentage of patients with 
INR <1.3 within 3 hours of 
treatment
PCC (vs FFP) had a higher rate of INR 
reversal
UPRATE42–44 Rivaroxaban, 
apixaban
4F- PCC Haemostasis rate 4F- PCC reverses apixaban and 
rivaroxaban associated bleeding
REVERSE- AD43 Dabigatran Idarucizumab Percentage reversal at 
4 hours
Idarucizumab reverses the effect of 
dabigatran for most patients (93%) within 
minutes
ANNEXA-444 Rivaroxaban, 
apixaban
Andexanet alfa Change in anti- Xa activity at 
12 hours
80% of those with DOAC associated ICH 
achieved excellent or good haemostasis 
12 hours after andexanet alfa
SPOTLIGHT and 
STOP- IT46
… rFVIIa Parenchymal ICH volume 
expansion on head CT at 
24 hours
rFVIIa does not improve radiographic 
findings
DOAC, direct- acting oral anticoagulant; FFP, fresh frozen plasma; ICH, intracerebral haemorrhage; INR, international normalised ratio; PCC, 
prothrombin complex concentrate; VKA, vitamin K antagonist.
Figure 1 Algorithm for the reversal of specific anticoagulants, including direct thrombin inhibitors, direct factor Xa inhibitors, 
warfarin and heparin. FFP, fresh frozen plasma; 4F- PCC,four factor prothrombin complex concentrate;ICH, intracerebral 
haemorrhage; INR, internationalnormalised ratio; IU, international unit; IV,intravenous; LMWH, low- molecular weight heparin; 
PCC,prothrombin complex concentrate.
There are anticoagulant reversal agents specific for 
different DOACs (tables 1 and 2). Idarucizumab is a mono-
clonal antibody that binds dabigatran. REVERSE- AD trial 
(Reversal Effects of Idarucizumab on Active Dabigatran) 
enrolled patients with active bleeding and patients that 
need reversal of anticoagulation prior to a procedure. 
Unfortunately, the study was was not designed for patients 
with ICH. Therefore it lacked objective measurement of 
clinical haemostasis in ICH.46 Nevertheless, idarucizumab 
was shown to reverse the effect of dabigatran for approxi-
mately 93% of patients within minutes.48
Recently, the Food and Drug Administration approved 
andexanet alfa, the second DOAC specific reversal 
agent. It is an elegant reversal agent for FXa- Is. It is a 
recombinant FXa that binds FXa- I. The ANNEXA-4 trial 
(Andexanet Alfa, a Novel Antidote to the Anticoagulation 
Effects of FXA Inhibitors) had 168 patients with ICH.47 
Haemostatic efficacy was measured via serial CT scans. Of 
those with ICH, 80% achieved excellent or good haemo-
stasis 12 hours after infusion. Excellent haemostasis was 
defined as haematoma growth <20% and good as <35% at 
12 hours. The study has limitations, it excluded patients 
with ICH with Glasgow Coma Scale <7 and ICH with 
volume >60 mL.47
on reCombInAnT ACTIVATed CoAgulATIon fACTor VII
There is a growing interest in recombinant activated factor 
VII (rFVIIa) in all forms of active bleeding associated with 
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coagulopathy. It was recently compared with placebo in 
patients with ICH and a spot sign on CT angiography. The 
study analysed 69 patients pooled from the SPOTLIGHT 
(‘Spot Sign’ Selection of Intracerebral Haemorrhage to 
Guide Haemostatic Therapy) and STOP- IT (The Spot 
Sign for Predicting and Treating ICH Growth Study) trials. 
These trials were closely coordinated between the investi-
gators in Canada (SPOTLIGHT) and the USA (STOP- IT). 
Patients were given rFVIIa within 3 hours of stroke onset. 
The primary outcome was parenchymal ICH volume expan-
sion and the secondary outcome was total haemorrhage 
volume expansion on head CT at 24 hours. The drug did 
not improve radiographic findings or outcomes compared 
with placebo. Baseline media ICH volumes were 19.6 (9.6 
to 39.2) mL in the rFVIIa group and 20.4 (8.6 to 32.6) mL 
in the placebo.49 This further adds to the growing evidence 
against rFVIIa as a reversal agent.
ConClusIon
Anticoagulation associated with ICH remains under 
investigated. Ironically, an indication for anticoagula-
tion is prevention of stroke. Though studies are showing 
DOACs lower the risk of bleeding associated complica-
tions compared with VKAs, there is paucity of strong data 
for the reversal of coagulopathy in ICH. Larger and more 
robust clinical trials targeting ICH are needed. Reversal 
agents need direct comparison against four factor PCC. 
Based on the current literature and standard of care, 
we developed a suggested algorithm for coagulopathy 
reversal in ICH (figure 1).
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